Hailong Zhang

发表

NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.

Jing Wu, P. Atadja, M. Hu, 2013, Cancer research.

Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation*

Jidong Zhu, P. Atadja, E. Li, 2011, The Journal of Biological Chemistry.

Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED

P. Atadja, E. Li, D. Bussiere, 2017, PloS one.

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.

M. P. Dillon, P. Atadja, Youzhen Wang, 2017, Journal of medicinal chemistry.

Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase.

M. P. Dillon, M. Lindvall, D. Bussiere, 2017, Journal of medicinal chemistry.

Therapeutics , Targets , and Chemical Biology NSD 2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

P. Atadja, E. Li, Jun Liu, 2013 .

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain

P. Atadja, E. Li, C. Arrowsmith, 2018, SLAS discovery : advancing life sciences R & D.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

P. Atadja, E. Li, Youzhen Wang, 2017, Nature chemical biology.

An allosteric PRC 2 inhibitor targeting the H 3 K 27 me 3 binding pocket of EED

P. Atadja, E. Li, Youzhen Wang, 2016 .